Biohaven Pharmaceuticals Inc. has signed a licensing agreement with pharma giant AstraZeneca for a new drug to treat a rare neurodegenerative disease.

The drug inhibits MPO, a key driver of oxidative and inflammatory processes, high levels of which have been linked to brain disorders like multiple sclerosis and Alzheimer’s disease.